(AOF) – Pharnext announces a fundraising of 800,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. The biotech developing new therapies for neurodegenerative diseases without satisfactory therapeutic solution, specifies that before the draw announced today, the issue of Oceane-BSA raised 34.9 million euros, gave rise to the creation of 29,627,273,836 new shares and could still give rise to the creation of 364,586 shares news based on the last quoted price.
The participation of a shareholder holding 1% of the capital prior to these drawings is today less than 0.0008%.
The issue of Oceane-BSA announced today gave rise to the issue of 160,000 BSAs and could give rise to the creation of 2,238,300 new shares based on the last listed price. The participation of a shareholder holding 1% of the capital prior to this new drawing would be 0.80%.
All of the Oceane-BSA issues carried out to date could result in the creation of 2,602,886 new shares based on the last listed price. The participation of a shareholder holding 1% of the capital to date could thus amount to 0.76%
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.